Compare MBCN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBCN | DSGN |
|---|---|---|
| Founded | 1901 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.2M | 528.1M |
| IPO Year | N/A | 2021 |
| Metric | MBCN | DSGN |
|---|---|---|
| Price | $37.20 | $9.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $35.00 | $13.50 |
| AVG Volume (30 Days) | 15.5K | ★ 331.1K |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 48.42 | N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $75,400,000.00 | N/A |
| Revenue This Year | $19.98 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | $14.16 | ★ N/A |
| Revenue Growth | ★ 16.60 | N/A |
| 52 Week Low | $22.74 | $2.60 |
| 52 Week High | $37.68 | $10.31 |
| Indicator | MBCN | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.89 | 62.42 |
| Support Level | $35.33 | $9.00 |
| Resistance Level | $37.68 | $9.67 |
| Average True Range (ATR) | 0.80 | 0.67 |
| MACD | 0.18 | -0.05 |
| Stochastic Oscillator | 82.00 | 60.84 |
Middlefield Banc Corp is a bank holding company. It offers customers, banking services including checking, savings, negotiable order of withdrawal (NOW) accounts, money market accounts, time deposits, commercial loans, real estate loans, a variety of consumer loans, safe deposit facilities, and travelers' checks. It also provides online banking and bill payment services to individuals and online cash management services to business customers.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.